Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
1. FDA approved Zevaskyn, Abeona's gene therapy for RDEB. 2. Zevaskyn is priced at $3.1 million, higher than expected. 3. Analyst predicts significant sales potential, over $30 million by 2025. 4. Estimated peak U.S. sales for Zevaskyn could reach $600 million. 5. ABEO stock rose 23.77% following FDA approval announcement.